← Leaderboards
Anupriya Agarwal
Oregon Health & Science University
$8,829,719
Attributed
$11,753,164
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,790,664 · 10
By mechanism
U54$4,329,644 · 4
R01$3,646,926 · 2
U01$2,792,833 · 2
R00$738,301 · 1
K99$282,960 · 1
Top collaborators
- Lucy Ann Godley8 shared
- Emery H. Bresnick4 shared
- Nancy Asmussen Speck4 shared
- Brian J Druker1 shared
- Shannon K Mcweeney1 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Mona Mohammadhosseini$143,420
- Haijiao Zhang$1,696,427
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionResponseCellsPathway InteractionsSamplingMediatingLeukemiaCytokineDrug ResistanceTherapeutic TargetInflammatoryMouse ModelMutationMolecularBone MarrowIn VitroGrowthMalignant NeoplasmsIn VivoAcute Myelocytic LeukemiaTransgenic MiceComplexResistanceAcute Myeloid Leukemia Cell
Grant awards (32)
The role of inflammation in driving leukemogenesis in germline predisposition syndromes$497,412
U01 · FY2025 · CA
Trajectory and Architecture of Microenvironment-Mediated Resistance in AMLÂ$304,153
U54 · FY2025 · CA · contact PI
Contribution of Inflammation to the Pathogenesis of RUNX1-FPDMM$37,500
U54 · FY2025 · CA · contact PI
Trajectory and Architecture of Microenvironment-Mediated Resistance in AMLÂ$37,500
U54 · FY2025 · CA · contact PI
The role of inflammation in driving leukemogenesis in germline predisposition syndromes$622,915
U01 · FY2024 · CA
Hematopoiesis in germline RUNX1mutation carriers: impact of inflammation and the bone marrow niche$504,283
R01 · FY2024 · HL · contact PI
Trajectory and Architecture of Microenvironment-Mediated Resistance in AMLÂ$291,065
U54 · FY2024 · CA · contact PI
Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML$277,069
U01 · FY2024 · CA · contact PI
The role of inflammation in driving leukemogenesis in germline predisposition syndromes$687,587
U01 · FY2023 · CA
Hematopoiesis in germline RUNX1mutation carriers: impact of inflammation and the bone marrow niche$516,884
R01 · FY2023 · HL · contact PI
Trajectory and Architecture of Microenvironment-Mediated Resistance in AMLÂ$304,153
U54 · FY2023 · CA · contact PI
Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML$285,818
R01 · FY2023 · CA · contact PI
The role of inflammation in driving leukemogenesis in germline predisposition syndromes$707,850
U01 · FY2022 · CA
Hematopoiesis in germline RUNX1mutation carriers: impact of inflammation and the bone marrow niche$519,194
R01 · FY2022 · HL · contact PI
Trajectory and Architecture of Microenvironment-Mediated Resistance in AMLÂ$369,603
U54 · FY2022 · CA · contact PI
Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML$113,769
R01 · FY2022 · CA · contact PI
Hematopoiesis in germline RUNX1mutation carriers: impact of inflammation and the bone marrow niche$532,884
R01 · FY2021 · HL · contact PI
Impact of Leukemia Microenvironment on Response to Targeted Therapies in AML$363,916
U54 · FY2021 · CA · contact PI
Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML$349,698
R01 · FY2021 · CA · contact PI
Impact of Leukemia Microenvironment on Response to Targeted Therapies in AML$363,916
U54 · FY2020 · CA · contact PI
Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML$349,698
R01 · FY2020 · CA · contact PI
Studying drug resistance in AML and PDAC using a novel heterotypic 3D organoid model$125,000
R01 · FY2020 · CA · contact PI
Impact of Leukemia Microenvironment on Response to Targeted Therapies in AML$450,830
U54 · FY2019 · CA · contact PI
Genetics and Signaling of Drug Resistance and Sensitivity in AML Cell Lines, Xenografts, and Primary Patient Samples$351,344
U54 · FY2019 · CA · contact PI
Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML$349,698
R01 · FY2019 · CA · contact PI
Genetics and Signaling of Drug Resistance and Sensitivity in AML Cell Lines, Xenografts, and Primary Patient Samples$727,832
U54 · FY2017 · CA · contact PI
Impact of Leukemia Microenvironment on Response to Targeted Therapies in AML$727,832
U54 · FY2017 · CA · contact PI
Role of p27 in chronic myeloid leukemia and its potential as a therapeutic target$248,246
R00 · FY2016 · CA · contact PI
Role of p27 in chronic myeloid leukemia and its potential as a therapeutic target$248,585
R00 · FY2015 · CA · contact PI
Role of p27 in chronic myeloid leukemia and its potential as a therapeutic target$241,470
R00 · FY2014 · CA · contact PI
Role of p27 in chronic myeloid leukemia and its potential as a therapeutic target$141,480
K99 · FY2012 · CA · contact PI
Role of p27 in chronic myeloid leukemia and its potential as a therapeutic target$141,480
K99 · FY2011 · CA · contact PI